Mattias N. E. Forsell

Mattias N. E. Forsell

Auto-generated profile, based on publicly available information

Mattias N. E. Forsell

Department of Clinical Microbiology, Umeå University, Umeå, Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Science Immunology
Verified
Journal Article
Open access
CKChengzi I. Kaku
Chengzi I. Kaku
ABAlan J. Bergeron
Alan J. Bergeron
CAClas Ahlm
Clas Ahlm
JNJohan Normark
Johan Normark
MSMrunal Sakharkar
Mrunal Sakharkar
LWLaura M. Walker
Laura M. Walker
Understanding immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection will facilitate the development of next-generation vaccines. Here, we profiled spike (S)–specific B cell responses after Omicron/BA.1 infection in messenger RNA–vaccinated donors. The acute antibody response was characterized by high levels of somatic hypermutation and a bias toward recognition of ancestral SARS-CoV-2 strains, suggesting the early activation of vaccine-induced memory B cells. BA.1 breakthrough infection induced a shift in B cell immunodominance hierarchy from the S2 subunit, which is highly conserved across SARS-CoV-2 variants of concern (VOCs), and toward the antigenically variable receptor binding domain (RBD). A large proportion of RBD-directed neutralizing antibodies isolated from BA.1 breakthrough infection donors displayed convergent sequence features and broadly recognized SARS-CoV-2 VOCs. Together, these findings provide insights into the role of preexisting immunity in shaping the B cell response to heterologous SARS-CoV-2 variant exposure.

9 September 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JNJohan Normark
Johan Normark
LVLinnea Vikström
Linnea Vikström
YGYong-Dae Gwon
Yong-Dae Gwon
IPIda-Lisa Persson
Ida-Lisa Persson
AEAlicia Edin
Alicia Edin
MFMattias Forsell
Mattias Forsell
Because of concerns about thrombotic events after vaccination with ChAdOx1 nCoV-19 (Oxford–AstraZeneca),1 several European countries have recommended heterologous messenger RNA (mRNA) boost strategies for persons younger than 60 or 65 years of age who have received one dose of ChAdOx1 nCoV-19.2 To date, data on the safety and immunogenicity of these regimens are limited.

4 March 2022 in Science
Verified
Journal Article
Open access
CKChengzi I. Kaku
Chengzi I. Kaku
ECElizabeth R. Champney
Elizabeth R. Champney
JNJohan Normark
Johan Normark
MGMarina Garcia
Marina Garcia
CJCarl E. Johnson
Carl E. Johnson
LWLaura M. Walker
Laura M. Walker
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC) responses in individuals who received either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous messenger RNA (mRNA) booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared with that of homologous ChAdOx1 boosting. Specificity mapping of circulating B cells revealed that mRNA-1273 boost immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273–boosted participants displayed overall higher binding affinities and increased breadth of reactivity against VOCs relative to those isolated from ChAdOx1-boosted individuals. Overall, the results provide molecular insight into the enhanced quality of the B cell response induced after heterologous mRNA booster vaccination.

2 May 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
CSChristopher Sundling
Christopher Sundling
CRCaroline Rönnberg
Caroline Rönnberg
VYVictor Yman
Victor Yman
Muhammad AsgharMuhammad Asghar
Muhammad Asghar
PJPeter Jahnmatz
Peter Jahnmatz
AFAnna Färnert
Anna Färnert
Humoral immunity is important in limiting clinical disease in malaria, yet the longitudinal B cell response to infection remains unclear. We performed a 1-year prospective study in patients treated for acute Plasmodium falciparum malaria for the first time or with previous exposure to the disease. Using an unbiased exploratory approach with mass cytometry, followed by targeted flow cytometry, we found that approximately 80% of mature B cells that proliferated in response to acute infection expressed CD11c. Only approximately 40% of CD11c + B cells displayed an atypical B cell phenotype, with the remaining cells primarily made up of activated and resting memory B cells. The CD11c + B cells expanded rapidly following infection, with previous exposure to malaria resulting in a significantly larger increase compared with individuals with primary infection. This was attributed to an expansion of switched CD11c + B cells that was absent in primary infected individuals. The rate of contraction of the CD11c + B cell compartment was independent of previous exposure to malaria and displayed a slow decay, with a half-life of approximately 300 days. Collectively, these results identify CD11c as a marker of B cells responding to malaria and further highlight differences in primary and secondary B cell responses during infection.

16 March 2022 in Science Translational Medicine
Verified
Journal Article
Open access
EMEva Mittler
Eva Mittler
AWAnna Z. Wec
Anna Z. Wec
JTJanne Tynell
Janne Tynell
Pablo Guardado-CalvoPablo Guardado-Calvo
Pablo Guardado-Calvo
JWJulia Wigren-Byström
Julia Wigren-Byström
KCKartik Chandran
Kartik Chandran
The rodent-borne hantavirus Puumala virus (PUUV) and related agents cause hemorrhagic fever with renal syndrome (HFRS) in humans. Other hantaviruses, including Andes virus (ANDV) and Sin Nombre virus, cause a distinct zoonotic disease, hantavirus cardiopulmonary syndrome (HCPS). Although these infections are severe and have substantial case fatality rates, no FDA-approved hantavirus countermeasures are available. Recent work suggests that monoclonal antibodies may have therapeutic utility. We describe here the isolation of human neutralizing antibodies (nAbs) against tetrameric Gn/Gc glycoprotein spikes from PUUV-experienced donors. We define a dominant class of nAbs recognizing the “capping loop” of Gn that masks the hydrophobic fusion loops in Gc. A subset of nAbs in this class, including ADI-42898, bound Gn/Gc complexes but not Gn alone, strongly suggesting that they recognize a quaternary epitope encompassing both Gn and Gc. ADI-42898 blocked the cell entry of seven HCPS- and HFRS-associated hantaviruses, and single doses of this nAb could protect Syrian hamsters and bank voles challenged with the highly virulent HCPS-causing ANDV and HFRS-causing PUUV, respectively. ADI-42898 is a promising candidate for clinical development as a countermeasure for both HCPS and HFRS, and its mode of Gn/Gc recognition informs the development of broadly protective hantavirus vaccines.

22 November 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
ACAlberto Cagigi
Alberto Cagigi
MYMeng Yu
Meng Yu
BÖBjörn Österberg
Björn Österberg
JSJulia Svensson
Julia Svensson
SFSara Falck-Jones
Sara Falck-Jones
ASAnna Smed-Sörensen
Anna Smed-Sörensen
Understanding the presence and durability of antibodies against SARS-CoV-2 in the airways is required to provide insights into the ability of individuals to neutralize the virus locally and prevent viral spread. Here, we longitudinally assessed both systemic and airway immune responses upon SARS-CoV-2 infection in a clinically well-characterized cohort of 147 infected individuals representing the full spectrum of COVID-19 severity, from asymptomatic infection to fatal disease. In addition, we evaluated how SARS-CoV-2 vaccination influenced the antibody responses in a subset of these individuals during convalescence as compared with naive individuals. Not only systemic but also airway antibody responses correlated with the degree of COVID-19 disease severity. However, although systemic IgG levels were durable for up to 8 months, airway IgG and IgA declined significantly within 3 months. After vaccination, there was an increase in both systemic and airway antibodies, in particular IgG, often exceeding the levels found during acute disease. In contrast, naive individuals showed low airway antibodies after vaccination. In the former COVID-19 patients, airway antibody levels were significantly elevated after the boost vaccination, highlighting the importance of prime and boost vaccinations for previously infected individuals to obtain optimal mucosal protection.